Implantica Dirección

Dirección controles de criterios 3/4

El CEO de Implantica es Peter Forsell , nombrado en Jan 2015, tiene una permanencia de 9.83 años. compensación anual total es €204.27K, compuesta por 99.8% salario y 0.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 87.11% de las acciones de la empresa, por valor de SEK9.06B. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 4.8 años, respectivamente.

Información clave

Peter Forsell

Chief Executive Officer (CEO)

€204.3k

Compensación total

Porcentaje del salario del CEO	99.8%
Permanencia del CEO	9.8yrs
Participación del CEO	87.1%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Peter Forsell en comparación con los beneficios de Implantica?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-€25m
Jun 30 2024	n/a	n/a	-€24m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€204k	€204k	-€24m
Sep 30 2023	n/a	n/a	-€20m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€21m
Dec 31 2022	€200k	€200k	-€21m

Compensación vs. Mercado: La compensación total de Peter($USD215.68K) está por debajo de la media de empresas de tamaño similar en el mercado Swedish ($USD778.01K).

Compensación vs. Ingresos: La compensación de Peter ha aumentado mientras la empresa no es rentable.

CEO

Peter Forsell (70 yo)

9.8yrs

Permanencia

€204,274

Compensación

Dr. Peter Forsell founded Implantica AG in 2015 and serves as its Chief Executive Officer since 2015.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Forsell	Founder & CEO	9.8yrs	€204.27k	87.11% SEK 9.1b
Andreas Öhrnberg	Chief Financial Officer	4.8yrs	sin datos	0.0084% SEK 877.1k
Stephan Siegenthaler	Chief Strategy Officer & Board Member	no data	sin datos	0.32% SEK 33.1m
Nicole Pehrsson	Chief Corporate Affairs Officer	2.4yrs	sin datos	0.17% SEK 17.7m
Amit Kukreja	Chief Market Access & Strategy Officer	3.8yrs	sin datos	sin datos
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	sin datos	sin datos

4.3yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMP A SDB se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephan Siegenthaler	Chief Strategy Officer & Board Member	4.8yrs	sin datos	0.32% SEK 33.1m
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	sin datos	sin datos
Liselott Kilaas	Independent Chair of the Board	4.8yrs	€36.02k	0.0099% SEK 1.0m
Tomas Puusepp	Independent Board Member	4.3yrs	€50.43k	0.0071% SEK 734.5k
Felix Zulauf	Member of Advisory Board	no data	sin datos	sin datos
Johan Bojs	Vice-Chairman of the Board	4.8yrs	€10.29k	0.047% SEK 4.9m
Piet Pattyn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Steven Wilson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kaspar Z'graggen	Member of Scientific Advisory Board	no data	sin datos	sin datos

4.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de IMP A SDB se considera experimentada (4.8 años de antigüedad promedio).

Implantica Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Implantica AG, Annual General Meeting, May 22, 2024

Chief Corporate Affairs Officer recently bought kr1.2m worth of stock

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Consensus revenue estimates decrease by 33%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG to Report Q4, 2024 Results on Feb 14, 2025

Implantica AG (publ.) Submits FDA PMA Application Clinical Module 2 for RefluxStop for U.S. Market Approval

Implantica AG to Report Q3, 2024 Results on Nov 15, 2024

Implantica Ag (Publ.) Announces Highly Successful 2024 American Foregut Society Meeting Where Refluxstop Received Remarkable Pre- Launch Market Feedback

Implantica AG announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop

Implantica AG Announces Excellent Data from an Independent Study of 158 RefluxStop Patients from Two Centers in Germany - Presented at the AUGIS Meeting in UK

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Consensus revenue estimates decrease by 17%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG Announces Refluxstop Pivotal 4-Year Study Results Published in the Prestigious Journal Surgical Endoscopy

Implantica Announces Continuing Progress in Modular PMA Application to FDA for Refluxstop

Implantica Announces New Health-economics Data Publication Showing RefluxStop's Superior Cost-Effectiveness for the Swiss Healthcare System

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Implantica Submits U.S. FDA Premarket Approval (PMA) Application for RefluxStop® (first module)

Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Implantica AG, Annual General Meeting, May 22, 2024

Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin

New minor risk - Share price stability

Chief Corporate Affairs Officer recently bought kr1.2m worth of stock

Consensus revenue estimates increase by 27%

Consensus revenue estimates fall by 27%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK

Insufficient new directors

Implantica AG to Report Q4, 2023 Results on Feb 20, 2024

Implantica AG to Report Q2, 2023 Results on Aug 24, 2023

New minor risk - Share price stability

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 21%, EPS upgraded

Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago

Implantica AG to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 35%, EPS upgraded

Full year 2022 earnings released: €0.30 loss per share (vs €0.055 loss in FY 2021)

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG to Report Q4, 2022 Results on Feb 17, 2023

Implantica AG to Report Q1, 2022 Results on May 11, 2022

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Implantica Ag Announces Launch of Refluxstop™ in Uk

Consensus revenue estimates increase by 13%

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

Full year 2021 earnings: EPS exceeds analyst expectations

Implantica AG to Report Q4, 2021 Results on Feb 18, 2022

Consensus forecasts updated

Implantica AG Appoints Paul Meadas as Chief Operating Officer

We're Not Very Worried About Implantica's (STO:IMP A SDB) Cash Burn Rate

High number of new and inexperienced directors

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Vice-Chairman of the Board recently sold kr14m worth of stock

Second quarter 2021 earnings released: €0.04 loss per share (vs €0.10 loss in 2Q 2020)

Implantica Achieves Regulatory Authorisation for RefluxStop™ in New Zealand

Implantica AG (publ) Makes Headway in Italy and Spain with Its Medical Device RefluxStop™

Implantica Advances in Sweden with its Medical Device Refluxstop™

Revenue behind estimates

Implantica AG to Report Q4, 2020 Results on Feb 25, 2021

Implantica AG (publ)'s RefluxStop™ Makes Strides in the UK